ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
64 132,70
0,38%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. NextCure Inc (NXTC)

  7. NextCure Inc (NXTC) Actualités

NXTC NextCure Inc

1,48
-0,01 (-0,67%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
NextCure Inc NXTC NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,01 -0,67% 1,48 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,60 1,49 1,60 1,53 1,49
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
02/5/202422:05GLOBENextCure Provides Business Update and Reports First Quarter..
24/4/202422:05GLOBENextCure to Present Phase 1b Data of NC410 in Combination..
08/4/202413:00GLOBENextCure and LCB Present Preclinical Data on B7-H4 Antibody..
04/4/202413:05GLOBENextCure Appoints Dr. Rakesh Dixit to Scientific Advisory..
02/4/202413:00GLOBENextCure to Present at 23rd Annual Needham Virtual..
21/3/202413:55GLOBENextCure Provides Business Update and Reports Full Year 2023..
05/3/202414:05GLOBENextCure Publishes Preclinical Data Demonstrating Function..
01/2/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202422:05GLOBENextCure Presents Preclinical Data on a Novel Therapeutic..
21/12/202313:05GLOBENextCure Publishes Non-Clinical Data Demonstrating..
14/12/202313:15EDGAR2Form 8-K - Current report
14/12/202312:45GLOBENextCure Provides Year-End Clinical Pipeline Updates
20/11/202313:00GLOBENextCure to Present at the 35th Annual Piper Sandler..
15/11/202322:05GLOBENextCure Publishes Non-Clinical Data Defining the Mechanism..
02/11/202321:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202321:10EDGAR2Form 8-K - Current report
02/11/202321:05GLOBENextCure Provides Business Update and Reports Third Quarter..
17/10/202314:05GLOBEPreclinical Data Demonstrate Anti-Siglec-15 Treatment..
26/9/202322:05GLOBENextCure Presents Preclinical Data on NC181, a Novel..
12/9/202314:05GLOBEA Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in..
07/9/202322:05GLOBENextCure and Nordic Bioscience Publish Review Article on the..
05/9/202322:05GLOBEPreclinical Data Demonstrate Potential Application of..
31/8/202313:00GLOBENextCure to Present at the H.C. Wainwright 25th Annual..
04/8/202322:58EDGAR2Form S-8 - Securities to be offered to employees in employee..
04/8/202322:30EDGAR2Form S-3 - Registration statement under Securities Act of..
03/8/202322:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202322:16EDGAR2Form 8-K - Current report
03/8/202322:05GLOBENextCure Provides Business Update and Reports Second Quarter..
19/7/202322:05EDGAR2Form 8-K - Current report
21/6/202322:05GLOBENextCure Presents Non-Clinical Data Defining the Mechanism..
09/5/202313:00GLOBENextCure to Present at the JMP Securities Life Sciences..

Dernières Valeurs Consultées

NASDAQ
NXTC
NextCure
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés